NYSE: NVO
Novo Nordisk A S Stock

NVO Price
$70.85
Fair Value Price
N/A
Market Cap
$167.06B
52 Week Low
$49.46
52 Week High
$73.62
P/E
4.02x
P/B
2.78x
P/S
8.08x
PEG
N/A
Dividend Yield
1.75%
Revenue
$126.58B
Earnings
$41.43B
Gross Profit Margin
83.70%
Operating Margin
43.52%
Net Profit Margin
32.70%
Debt to Equity
1.27
Operating Cash Flow
$56B
Beta
0.61
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

Zen Score

High
Medium
Low
37
Industry average

Reasons for this score

NVO ($70.85) is trading above its intrinsic value of -$1,906.29, according to Benjamin Graham's Formula from Chapter 14 of "The Intelligent Investor"
Valuation
NVO is good value based on its earnings relative to its share price (4.02x), compared to the US market average 38.92x)
Valuation
NVO is good value based on its earnings relative to its share price (4.02x), compared to the US Biotechnology industry average (-12.21x)
Valuation

1 of 12

NVO News

Valuation

NVO price to earnings (PE)

For valuing profitable companies with steady earnings
Company
4.02x
Industry
-12.21x
Market
38.92x
NVO is good value based on its earnings relative to its share price (4.02x), compared to the US market average 38.92x)
Valuation
NVO is good value based on its earnings relative to its share price (4.02x), compared to the US Biotechnology industry average (-12.21x)
Valuation

NVO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.78x
Industry
2.07x
Market
65.04x
NVO is good value based on its book value relative to its share price (2.78x), compared to the US market average (65.04x)
Valuation
NVO is poor value based on its book value relative to its share price (2.78x), compared to the US Biotechnology industry average (2.07x)
Valuation

NVO's financial health

Profit margin

Revenue
$33.9B
Net Income
$11.9B
Profit Margin
35.10%
NVO's Earnings (EBIT) of $55.08B can safely cover interest payments on company debt ($4.14B)
Financials
NVO's profit margin has decreased (-0.20%) in the last year from (32.90%) to (32.70%)
Financials

Assets to liabilities

Assets
$126.3B
Liabilities
$71.9B
Debt to equity
0.08
NVO's short-term assets ($73.58B) exceed its short-term liabilities ($67.28B)
Financials
NVO's short-term assets ($73.58B) exceed its long-term liabilities ($8.78B)
Financials
NVO's debt has increased relative to shareholder equity (1.27), over the past 5 years ago (1.08)
Financials
NVO's debt to equity ratio (1.27) is considered high
Financials

Cash flow

Operating
$10.0B
Investing
-$2.1B
Financing
-$13.5B
NVO's operating cash flow ($56.13B) is sufficient to service the company's debt ($4.14B)
Financials

Novo Nordisk A S Stock FAQ

(NYSE: NVO) Novo Nordisk A S trades on the NYSE under the ticker symbol NVO. Novo Nordisk A S stock quotes can also be displayed as NYSE: NVO.
(NYSE: NVO) Novo Nordisk A S stock price per share is $70.85 today (as of Oct 21, 2020).
(NYSE: NVO) Novo Nordisk A S's 52-week high was $73.62, and its 52-week low was $49.46. It is currently -3.76% from its 52-week high and 43.25% from its 52-week low.
(NYSE: NVO) Novo Nordisk A S's market cap is $167.06B, as of Oct 22, 2020.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Novo Nordisk A S's market cap is calculated by multiplying NVO's current stock price of $70.85 by NVO's total outstanding shares of 2,357,900,000.
(NYSE: NVO) Novo Nordisk A S currently has 2,357,900,000 outstanding shares. With Novo Nordisk A S stock trading at $70.85 per share, the total value of Novo Nordisk A S stock (market capitalization) is $167.06B.

Novo Nordisk A S stock was originally listed at a price of $2.89 in Dec 31, 1997. If you had invested in Novo Nordisk A S stock at $2.89, your return over the last 22 years would have been 2,355.81%, for an annualized return of 15.66%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics